EA201591844A1 - 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-ht4 рецептора - Google Patents

5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-ht4 рецептора

Info

Publication number
EA201591844A1
EA201591844A1 EA201591844A EA201591844A EA201591844A1 EA 201591844 A1 EA201591844 A1 EA 201591844A1 EA 201591844 A EA201591844 A EA 201591844A EA 201591844 A EA201591844 A EA 201591844A EA 201591844 A1 EA201591844 A1 EA 201591844A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
receptor
quinolin
amino
carboxamide derivatives
Prior art date
Application number
EA201591844A
Other languages
English (en)
Other versions
EA029365B1 (ru
Inventor
Рамакришна Нироджи
Анил Карбхари Схинде
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA201591844A1 publication Critical patent/EA201591844A1/ru
Publication of EA029365B1 publication Critical patent/EA029365B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Настоящее изобретение относится к новым хинолиновым соединениям формулы (I), их фармацевтически приемлемым солям и к способу их получения. Соединения формулы (I) являются полезными для лечения различных расстройств, которые связаны с агонистами 5-НТ4 рецепторов.
EA201591844A 2013-03-20 2013-10-18 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора EA029365B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
IN1199CH2013 IN2013CH01199A (ru) 2013-03-20 2013-10-18

Publications (2)

Publication Number Publication Date
EA201591844A1 true EA201591844A1 (ru) 2016-08-31
EA029365B1 EA029365B1 (ru) 2018-03-30

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591844A EA029365B1 (ru) 2013-03-20 2013-10-18 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора

Country Status (19)

Country Link
US (1) US9790211B2 (ru)
EP (1) EP2976337B1 (ru)
JP (1) JP6185650B2 (ru)
KR (1) KR101815307B1 (ru)
CN (1) CN105164119B (ru)
AP (1) AP2015008742A0 (ru)
AU (1) AU2013382944B2 (ru)
BR (1) BR112015024060A2 (ru)
CA (1) CA2907620C (ru)
DK (1) DK2976337T3 (ru)
EA (1) EA029365B1 (ru)
ES (1) ES2674993T3 (ru)
HK (1) HK1217483A1 (ru)
IN (1) IN2013CH01199A (ru)
MX (1) MX364929B (ru)
NZ (1) NZ712369A (ru)
SG (1) SG11201507763RA (ru)
WO (1) WO2014147636A1 (ru)
ZA (1) ZA201506804B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3265459T (lt) * 2015-02-13 2019-08-26 Suven Life Sciences Limited Amidų junginiai, kaip 5-ht4 receptorių agonistai
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5150393A (en) * 1992-10-13 1994-05-09 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
KR950704328A (ko) 1992-11-05 1995-11-17 데이비드 로버츠 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists)
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
AU2001225664A1 (en) * 2000-06-15 2001-12-24 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
DE602004009069T2 (de) * 2003-06-19 2008-06-19 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidinbenzamide als 5ht4-antagonisten
EP1689742B1 (en) 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
JP4740152B2 (ja) * 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
MX343165B (es) 2010-02-12 2016-10-26 Raqualia Pharma Inc Agonistas del receptor 5-ht4 para el tratamiento de demencia.
SG183111A1 (en) 2010-02-16 2012-09-27 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Also Published As

Publication number Publication date
SG11201507763RA (en) 2015-10-29
AU2013382944A1 (en) 2015-10-08
CA2907620C (en) 2018-03-13
NZ712369A (en) 2016-11-25
IN2013CH01199A (ru) 2015-08-14
MX364929B (es) 2019-05-14
KR101815307B1 (ko) 2018-01-04
CA2907620A1 (en) 2014-09-25
US20160280694A1 (en) 2016-09-29
EP2976337A1 (en) 2016-01-27
DK2976337T3 (en) 2018-07-16
US9790211B2 (en) 2017-10-17
AU2013382944B2 (en) 2016-08-04
WO2014147636A1 (en) 2014-09-25
EA029365B1 (ru) 2018-03-30
HK1217483A1 (zh) 2017-01-13
CN105164119A (zh) 2015-12-16
CN105164119B (zh) 2017-12-08
AP2015008742A0 (en) 2015-09-30
MX2015012350A (es) 2016-05-09
JP6185650B2 (ja) 2017-08-23
ZA201506804B (en) 2016-07-27
KR20160004274A (ko) 2016-01-12
WO2014147636A8 (en) 2014-12-04
JP2016516089A (ja) 2016-06-02
BR112015024060A2 (pt) 2017-07-18
EP2976337B1 (en) 2018-05-02
ES2674993T3 (es) 2018-07-05

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201500875A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201690844A1 (ru) Ингибиторы gsk-3
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201500931A1 (ru) Производные пиридин-4-ила
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201600434A1 (ru) Применение производных бензимидазолпролина
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201391744A1 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение в качестве ингибиторов киназы рецептора vegf

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU